Description

Envarsus (tacrolimus) tablets with prolonged release 4 mg. №30

Ingredients:

Each tablet contains 4 mg of tacrolimus.

Dosage:

The usual starting dose is 0.1 to 0.15 mg/kg/day. Dosage may vary based on individual patient factors. Consult a healthcare professional for personalized dosing.

Indications:

Envarsus tablets are indicated for the prophylaxis of organ rejection in adult kidney or liver transplant patients.

Contraindications:

Do not use Envarsus if you are allergic to tacrolimus or any of the ingredients in the formulation. Consult your doctor for alternative treatment options.

Directions:

Take Envarsus exactly as prescribed by your healthcare provider. Swallow the tablet whole with a full glass of water. Do not crush, chew, or break the tablet.

Scientific Evidence:

Studies have shown that Envarsus (tacrolimus) with prolonged release is effective in preventing organ rejection in transplant patients. The extended-release formulation provides a consistent drug level in the blood, reducing the frequency of dosing and improving patient adherence to therapy.

Additional Information:

It is important to monitor tacrolimus blood levels regularly to ensure therapeutic efficacy and prevent toxicity. Common side effects may include tremors, headache, hypertension, and gastrointestinal disturbances. Inform your healthcare provider if you experience any adverse reactions.

Envarsus offers a convenient dosing regimen and improved bioavailability compared to immediate-release tacrolimus formulations. Clinical trials have demonstrated the efficacy and safety of Envarsus in maintaining stable immunosuppression in transplant recipients, leading to better long-term outcomes.